The Prostatype® Test System was registered at the Swedish Medical Product Agency and is now CE‐approved. The approval met all requirements of 98/79/EC (IVD Directive) and is in full compliance with ISO 13485:2012.
A new paper from Chunde Li’s research group, validating that the gene expression of IGFBP3 and F3 in prostate cancer tissue can provide an improved survival prediction.
Peng Z et al., PLoS One. 2016 Jan 5;11(1):e0145545.
Chundsell Medicals is presenting the Prostatype® Test System at Urologidagarna 2015 in Karlstad.
At the Annual meeting of the Association for Molecular Pathology in Washington DC, Chundsell Medicals presented the latest published research results from the first part of the Prostatype® Validation Study.
Chunde Li’s research group published a new paper, showing that the choice of biopsies has limited impact on the gene signature.
Peng Z et al., PLoS One. 2014 Oct 8;9(10):e109610.